To evaluate the clinical efficacy of an Ayurvedic compound â??Drakshadi Lehaâ?? in the Management of Iron Deficiency Anemia in children.

Study of Prevalence of Iron Deficiency Anemia in Children and Efficacy of Drakshadi Leha in its Management

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/018911

Enrollment

Registered

2019-05-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E638- Other specified nutritional deficiencies

Interventions

Intervention1: Drakshadi Leha, Iron & Folic Acid Tablets: Drakshadi Leha Dose-180-200 mg/kg/day in divided doses orally for 8 weeks. Iron & Folic Acid Tablets Dose: 1 Tablet daily (30 mg elemental iro

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects aged between 6-12 years 2. Subjects with iron deficiency anemia (Hb. 7 gm% -11.9 gm %). 3. Subjects whose parents are willing to give consent for clinical trial.

Exclusion criteria

Exclusion criteria: 1. Hemoglobin 2. Subjects suffering from major systemic illness necessitating long term treatment. 3. Subjects with evidence of malignancy. 4. Subjects with concurrent serious hepatic dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or renal dysfunction (defined as S. creatinine >1.2mg/dl), uncontrolled pulmonary dysfunction (asthmatic and COPD patients) 5. Co-morbidity like TB, UTI and bleeding disorders etc. 6. H/o hypersensitivity to any of the trial drug or their ingredients. 7. Subjects who have completed participation in any other clinical trial during the past six months.

Design outcomes

Primary

Measure	Time frame
Change in the subjective parameters of Iron Deficiency Anemia(Pandu) in Children. 1. Vaivarnya (pallor) 2. Aruchi (anorexia) 3. Daurbalyata (weakness) 4. Shrama (fatigueness) 5. Shvasha (dyspnoea) 6. Kopana (irritability) 7. Hridaya spandana (palpitation) 8. Shotha (oedema) 9. Karnakshveda (tinnitus) 10. Hatanala (indigestion) 11. Bhrama (giddiness) 12. SpleenomegalyTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Change in the objectives parameters. Hb%, RDW, RBC count, MCV, MCHC, PBS, TIBC, Serum IronTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Anukriti Guar

National Institute of Ayurveda

drannuguar764@gmail.com7597633909

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026